GlassScriptPhysician profile
Michael T Anderson
NPI 1346226164
$9,447.51
in general payments reported to CMS, 2019-2025
46 companies · $1,056 in 2025
The $1,056 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,136 · 2020: $1,244 · 2021: $2,031 · 2022: $1,604 · 2023: $1,087 · 2024: $1,289 · 2025: $1,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,431.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,742.92 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $1,127.96 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,044.82 | 2021-2024 | Qulipta, Vraylar, Ubrelvy |
| Novo Nordisk INC | $1,023.85 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $778.21 | 2019-2024 | Jardiance |
| Pfizer INC. | $365.55 | 2020-2025 | |
| Glaxosmithkline, LLC. | $337.72 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Sanofi-Aventis U.S. LLC | $258.73 | 2019-2023 | |
| Biohaven Pharmaceuticals, INC. | $246.25 | 2020-2021 | |
| Amgen INC. | $221.96 | 2019-2025 | Repatha, Otezla, Otezla |
| Allergan, INC. | $219.32 | 2019-2020 | |
| Exact Sciences Corporation | $214.31 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $212.94 | 2019-2023 | Vaxneuvance, Pneumovax 23, Gardasil 9 |
| Astellas Pharma US INC | $177.78 | 2019-2021 | |
| Amarin Pharma, INC. | $160.94 | 2020 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.